SCHEMBL25623930

SCHEMBL25623930

O=C(O)c1cnn(CC(F)F)c1Br

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.34
MAPT P10636 4/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
KDM4E B2RXH2 5/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
NR4A3 Q92570 1/20 0.33
POLB P06746 1/20 0.33
GRIA1 P42261 1/20 0.32
GRIA2 P42262 1/20 0.32
GRIA4 P48058 1/20 0.32
GRIK5 Q16478 1/20 0.32
ASPH Q12797 1/20 0.32
KDM8 Q8N371 1/20 0.32
NPC1 O15118 2/20 0.31
S1PR4 O95977 2/20 0.31
S1PR1 P21453 2/20 0.31
RAB9A P51151 2/20 0.31
MITF O75030 1/20 0.31
KMO O15229 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26135833 0.80 ALKBH1 (0.37) ALDH1A1MAPTSMN1; SMN2KDM4ENR4A3
SCHEMBL17438003 0.80 KDM4E (0.40) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL25109589 0.79 LMNA (0.45) ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10
SCHEMBL25108322 0.79 KDM4E (0.30) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL25108342 0.75
SCHEMBL21964592 0.72 HCAR2 (0.37) ALDH1A1MAPTSMN1; SMN2NR4A3POLB
SCHEMBL25623818 0.72 HTR2A (0.31)
SCHEMBL6379827 0.70 GRIA1 (0.36) POLBGRIA1GRIA2GRIA4GRIK5
SCHEMBL13184726 0.69 KDM4E (0.37) ALDH1A1MAPTSMN1; SMN2KDM4ENR4A3
SCHEMBL28976515 0.68 KDM4E (0.38) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667649-B2 Heteroaromatic macrocyclic ether chemotherapeutic agents NUVALENT, INC. (US) 2023-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667649-B2 Heteroaromatic macrocyclic ether chemotherapeutic agents CYP2C8, ABCB1, PAICS ALDH1A1 1313/4885MAPT 3344/4885SMN1; SMN2 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.